Feeling So Weak
After answering questions from a reporter from the People's Daily Newspaper Office, Shen Qi gave interviews to several other media outlets, both domestic and international.
One media outlet asked, "Professor Shen, in your report you mentioned that the research results on Macrocyclic Compounds have been applied in practical applications, and a new Macrocyclic Compounds, Triazatrisiloxanes, has been synthesized. We found in the official announcement from the CFDA that Triazatrisiloxanes has been approved to enter Phase I Clinical Trial."
Shen Qi: "Yes."
Media: "We've also learned that your wife participated in the Phase I Clinical Trial of Triazatrisiloxanes as a subject. Is this true?"
Shen Qi: "Yes."
Wow~
Wow~
Huh?
The media representatives present expressed a variety of opinions.
Soon, related news reports appeared online.
"On the second day of the IUPAC World Chemistry Congress, Academician Shen Qi publicly reported for the first time on the research progress of ' Macrocyclic Compounds, Novel Rearrangement Reactions, and the Application of Related Chemical Drugs,' which aroused enthusiastic responses."
According to chemists both at home and abroad, Shen Qi Team's research results are expected to win this year's Nobel Chemistry Prize.
"The actual product of <Macrocyclic Compounds, Novel Rearrangement Reactions and the Application of Related Chemical Drugs> is a chemical drug called Triazatrisiloxanes. Currently, this drug has entered Phase I Clinical Trial in China, and Shen Qi's wife is participating in the clinical trials as a subject."
The media reports were relatively objective; they presented the facts.
The comments and messages were varied and diverse.
"Using your wife for human experiments?"
"Can't afford to offend them, can't afford to offend them."
"I believe Academician Shen must have had enough confidence to do this."
"Actually, Academician Shen started this research project to cure his wife's illness, and then he accidentally won the Nobel Prize..."
"Stop joking. Although R-type Anemia is a rare disease, Madam Shen is not the only patient. Academician Shen is doing this to save patients all over the world."
"Regardless, I wish Academician Shen's research project success, and I wish patients all over the world a speedy recovery."
At 2 p. m., Shen Qi chaired a Q&A session on "Macrocyclic Compounds, Novel Rearrangement Reactions and the Application of Related Chemical Drugs" in Conference Room 2 of the Capital International Convention Center.
Conference Room No. 2, which can accommodate more than 80 people, was packed to capacity. Some late-arriving scholars had to stand, and the total number of attendees exceeded 100.
More than a thousand people attended the IUPAC World Chemistry Congress, but only about a hundred of them were truly renowned and accomplished scholars, and almost all of them were here.
"Everyone, you can ask questions now," Shen Qi said.
The first question came from a white scholar, "Professor Shen, I am Charlie Manson from Caltech. Triazatrisiloxanes Macrocyclic Compounds with this structure, fits your theory of Macrocyclic Compounds. However, we all know that there are many known and unknown Macrocyclic Compounds. How can you guarantee that your theory can be applied to all or most Macrocyclic Compounds?"
This is an excellent question; it reflects the sentiments of most participants and is a representative one.
Shen Qi replied, "My method is very traditional: derive the theory through experiments, and then verify the theory through experiments. Mr. Manson is right. How can I prove that my theory applies to all or most Macrocyclic Compounds? Experiments, yes, by conducting experiments."
"Our paper, 'Macrocyclic Compounds, Novel Rearrangement Reactions, and Applications of Related Chemical Drugs,' has been published. Our team has presented all the theoretical frameworks, reaction mechanisms, and practical applications we know without reservation. Our lab cannot verify all Macrocyclic Compounds, so we ask for your help in conducting verifications."
"If any research teams happen to be studying Macrocyclic Compounds, then I hope our book, <Macrocyclic Compounds, Novel Rearrangement Reactions, and Applications of Related Chemical Drugs>, can be helpful to your experiments, or at least prove to be wrong. Thank you, next."
The scholars present asked questions one by one, Shen Qi answered them one by one.
The Q&A session went very smoothly, with everyone exchanging ideas amicably and discussing things harmoniously.
Two hours passed quickly, and Shen Qi's answers to various questions satisfied most of the scholars.
In fact, Shen Qi had been waiting for a question from one person: Mr. Tachibana.
However, it seems that Mr. Tachibana did not attend the Q&A session.
The five-day IUPAC World Chemistry Congress has concluded, and the paper "Macrocyclic Compounds, Novel Rearrangement Reactions and Applications of Related Chemical Drugs" has been officially published in the conference proceedings for scholars worldwide to study and verify.
Shen Qi's chemistry level still hasn't been upgraded to level 14.
"Perhaps I'll have to wait until scholars all over the world verify that there are no problems before I can upgrade to level 14?" Shen Qi had a brief conversation with the system.
The system did not respond.
Yanjing University People's Hospital.
The clinical trial research team for Triazatrisiloxanes has begun administering the drug to subjects, including Ou Ye.
Typically, drugs in Phase I Clinical Trial are not expected to demonstrate any clinical efficacy. The primary considerations in conducting Phase I Clinical Trial are the safety, rights, and health status of the participants, as well as the scientific information that can be obtained from the clinical trial.
The first step in Phase I Clinical Trial is tolerability testing, which determines the dosage range within which the human body can tolerate the new drug.
During the tolerance test, Ou Ye's daily routine consisted of taking medication, undergoing electrocardiograms, routine blood/urine tests, liver and kidney function biochemical tests, RBC counts, HCT tests, etc., every day, in a very regular manner.
During this period, Shen Qi's work and life revolved entirely around the hospital, and he closely followed all the data and details of the Phase I Clinical Trial of Triazatrisiloxanes.
Shen Qi carefully studied the test data of all subjects from day one to today, and focused on studying Ou Ye's test data.
"Routine tests came back normal. RBC, HCT, hemoglobin concentration, and serum creatinine were all normal. That's good news, honey. How are you feeling?"
"I... I feel so weak..."
"This is a normal reaction. Even a healthy volunteer would feel weak after taking medication and undergoing so many tests every day. I analyzed your data, and your indicators are about the same as before; they haven't worsened or improved. In fact, during the tolerance trial phase, it's difficult for the research physicians and myself to determine the efficacy of Triazatrisiloxanes for patients. All we can determine is whether the drug is safe and what dosage the patient can tolerate, and so on. Again, no abnormalities are good news."
"Hmm... I know... I'll persevere... Nofi, is Nofi alright? Does Nofi miss me?"